Biotechnology
Compare Stocks
4 / 10Stock Comparison
CDT vs MRCC vs CSWC vs GAIN
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Asset Management
Asset Management
CDT vs MRCC vs CSWC vs GAIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Asset Management | Asset Management | Asset Management |
| Market Cap | $368K | $110M | $1.43B | $657M |
| Revenue (TTM) | $696M | $21M | $164M | $90M |
| Net Income (TTM) | $17M | $-5M | $103M | $130M |
| Gross Margin | 36.9% | 60.8% | 66.5% | 68.6% |
| Operating Margin | 6.4% | 51.7% | 48.5% | 72.7% |
| Forward P/E | 0.0x | 14.9x | 10.1x | 40.7x |
| Total Debt | $1.29B | $191M | $956M | $456M |
| Cash & Equiv. | $390M | $2M | $43M | $14M |
CDT vs MRCC vs CSWC vs GAIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 100 | 0.0 | -100.0% |
| Monroe Capital Corp… (MRCC) | 100 | 42.6 | -57.4% |
| Capital Southwest C… (CSWC) | 100 | 101.1 | +1.1% |
| Gladstone Investmen… (GAIN) | 100 | 102.4 | +2.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CDT vs MRCC vs CSWC vs GAIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CDT is the #2 pick in this set and the best alternative if growth and value is your priority.
- 8.9% revenue growth vs MRCC's -39.7%
- Lower P/E (0.0x vs 40.7x)
MRCC lags the leaders in this set but could rank higher in a more targeted comparison.
CSWC is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 3 yrs, beta 0.84, yield 10.2%
- Rev growth 7.7%, EPS growth -28.3%
- NIM 7.0% vs GAIN's 5.5%
- 10.2% yield, 3-year raise streak, vs GAIN's 10.0%, (1 stock pays no dividend)
GAIN carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 319.3% 10Y total return vs CSWC's 234.2%
- Lower volatility, beta 0.53, Low D/E 91.3%, current ratio 3.69x
- Beta 0.53, yield 10.0%, current ratio 3.69x
- 72.7% margin vs CDT's 2.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.9% revenue growth vs MRCC's -39.7% | |
| Value | Lower P/E (0.0x vs 40.7x) | |
| Quality / Margins | 72.7% margin vs CDT's 2.4% | |
| Stability / Safety | Beta 0.53 vs CDT's 1.84, lower leverage | |
| Dividends | 10.2% yield, 3-year raise streak, vs GAIN's 10.0%, (1 stock pays no dividend) | |
| Momentum (1Y) | +34.0% vs CDT's -99.8% | |
| Efficiency (ROA) | 10.5% ROA vs MRCC's -1.3%, ROIC 5.3% vs 2.0% |
CDT vs MRCC vs CSWC vs GAIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
CDT vs MRCC vs CSWC vs GAIN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GAIN leads in 1 of 6 categories
CDT leads 1 • CSWC leads 1 • MRCC leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GAIN leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CDT is the larger business by revenue, generating $696M annually — 32.8x MRCC's $21M. GAIN is the more profitable business, keeping 72.7% of every revenue dollar as net income compared to CDT's 2.4%.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $696M | $21M | $164M | $90M |
| EBITDAEarnings before interest/tax | $47M | $11M | $142M | $58M |
| Net IncomeAfter-tax profit | $17M | -$5M | $103M | $130M |
| Free Cash FlowCash after capex | -$6M | $25M | -$69M | -$82M |
| Gross MarginGross profit ÷ Revenue | +36.9% | +60.8% | +66.5% | +68.6% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +51.7% | +48.5% | +72.7% |
| Net MarginNet income ÷ Revenue | +2.4% | +53.8% | +43.1% | +72.7% |
| FCF MarginFCF ÷ Revenue | -0.9% | +5.5% | -132.6% | +126.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.4% | -51.5% | +113.3% | +58.1% |
Valuation Metrics
CDT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 0.0x trailing earnings, CDT trades at a 100% valuation discount to CSWC's 16.3x P/E. On an enterprise value basis, CDT's 2.4x EV/EBITDA is more attractive than CSWC's 27.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $367,825 | $110M | $1.4B | $657M |
| Enterprise ValueMkt cap + debt − cash | $896M | $108M | $2.3B | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | 0.00x | 9.58x | 16.32x | 9.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.94x | 10.06x | 40.66x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.21x | — | — |
| EV / EBITDAEnterprise value multiple | 2.43x | — | 27.43x | 16.82x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 3.55x | 8.71x | 7.31x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.66x | 1.39x | 1.22x |
| Price / FCFMarket cap ÷ FCF | — | 0.95x | — | 5.77x |
Profitability & Efficiency
Evenly matched — CDT and MRCC and GAIN each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
GAIN delivers a 21.9% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-3 for MRCC. GAIN carries lower financial leverage with a 0.91x debt-to-equity ratio, signaling a more conservative balance sheet compared to MRCC's 1.15x. On the Piotroski fundamental quality scale (0–9), CDT scores 6/9 vs CSWC's 1/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.6% | -2.9% | +10.3% | +21.9% |
| ROA (TTM)Return on assets | +1.0% | -1.3% | +4.8% | +10.5% |
| ROICReturn on invested capital | +21.9% | +2.0% | +3.5% | +5.3% |
| ROCEReturn on capital employed | +22.2% | +2.6% | +4.6% | +6.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 1 | 4 |
| Debt / EquityFinancial leverage | 1.02x | 1.15x | 1.08x | 0.91x |
| Net DebtTotal debt minus cash | $896M | $189M | $913M | $441M |
| Cash & Equiv.Liquid assets | $390M | $2M | $43M | $14M |
| Total DebtShort + long-term debt | $1.3B | $191M | $956M | $456M |
| Interest CoverageEBIT ÷ Interest expense | -1.05x | 0.69x | 2.91x | 1.58x |
Total Returns (Dividends Reinvested)
Evenly matched — CSWC and GAIN each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GAIN five years ago would be worth $17,205 today (with dividends reinvested), compared to $0 for CDT. Over the past 12 months, CSWC leads with a +34.0% total return vs CDT's -99.8%. The 3-year compound annual growth rate (CAGR) favors CSWC at 20.7% vs CDT's -97.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -94.2% | -11.4% | +11.4% | +20.7% |
| 1-Year ReturnPast 12 months | -99.8% | -6.8% | +34.0% | +30.8% |
| 3-Year ReturnCumulative with dividends | -100.0% | +18.0% | +75.8% | +56.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | -0.9% | +51.4% | +72.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | +22.8% | +234.2% | +319.3% |
| CAGR (3Y)Annualised 3-year return | -97.4% | +5.7% | +20.7% | +16.1% |
Risk & Volatility
Evenly matched — CSWC and GAIN each lead in 1 of 2 comparable metrics.
Risk & Volatility
GAIN is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than CDT's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CSWC currently trades 98.2% from its 52-week high vs CDT's 0.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.84x | 0.74x | 0.84x | 0.53x |
| 52-Week HighHighest price in past year | $1425.00 | $7.76 | $24.43 | $17.14 |
| 52-Week LowLowest price in past year | $1.20 | $4.04 | $19.37 | $13.11 |
| % of 52W HighCurrent price vs 52-week peak | +0.1% | +65.5% | +98.2% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 27.2 | 50.4 | 63.7 | 69.9 |
| Avg Volume (50D)Average daily shares traded | 126K | 156K | 664K | 371K |
Analyst Outlook
CSWC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MRCC as "Hold", CSWC as "Buy", GAIN as "Hold". Consensus price targets imply 57.5% upside for MRCC (target: $8) vs -9.1% for GAIN (target: $15). For income investors, CSWC offers the higher dividend yield at 10.20% vs MRCC's 0.24%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | — | $8.00 | $22.50 | $15.00 |
| # AnalystsCovering analysts | — | 11 | 10 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | +0.2% | +10.2% | +10.0% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 3 | 0 |
| Dividend / ShareAnnual DPS | — | $0.93 | $2.45 | $1.66 |
| Buyback YieldShare repurchases ÷ mkt cap | +28.8% | 0.0% | 0.0% | 0.0% |
GAIN leads in 1 of 6 categories (Income & Cash Flow). CDT leads in 1 (Valuation Metrics). 3 tied.
CDT vs MRCC vs CSWC vs GAIN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CDT or MRCC or CSWC or GAIN a better buy right now?
For growth investors, Capital Southwest Corporation (CSWC) is the stronger pick with 7.
7% revenue growth year-over-year, versus -39. 7% for Monroe Capital Corporation (MRCC). CDT Equity Inc. (CDT) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate Capital Southwest Corporation (CSWC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CDT or MRCC or CSWC or GAIN?
On trailing P/E, CDT Equity Inc.
(CDT) is the cheapest at 0. 0x versus Capital Southwest Corporation at 16. 3x. On forward P/E, Capital Southwest Corporation is actually cheaper at 10. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CDT or MRCC or CSWC or GAIN?
Over the past 5 years, Gladstone Investment Corporation (GAIN) delivered a total return of +72.
0%, compared to -100. 0% for CDT Equity Inc. (CDT). Over 10 years, the gap is even starker: GAIN returned +319. 3% versus CDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CDT or MRCC or CSWC or GAIN?
By beta (market sensitivity over 5 years), Gladstone Investment Corporation (GAIN) is the lower-risk stock at 0.
53β versus CDT Equity Inc. 's 1. 84β — meaning CDT is approximately 244% more volatile than GAIN relative to the S&P 500. On balance sheet safety, Gladstone Investment Corporation (GAIN) carries a lower debt/equity ratio of 91% versus 115% for Monroe Capital Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CDT or MRCC or CSWC or GAIN?
By revenue growth (latest reported year), Capital Southwest Corporation (CSWC) is pulling ahead at 7.
7% versus -39. 7% for Monroe Capital Corporation (MRCC). On earnings-per-share growth, the picture is similar: CDT Equity Inc. grew EPS 128. 8% year-over-year, compared to -28. 3% for Capital Southwest Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CDT or MRCC or CSWC or GAIN?
Gladstone Investment Corporation (GAIN) is the more profitable company, earning 72.
7% net margin versus 8. 7% for CDT Equity Inc. — meaning it keeps 72. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GAIN leads at 72. 7% versus 11. 6% for CDT. At the gross margin level — before operating expenses — GAIN leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CDT or MRCC or CSWC or GAIN more undervalued right now?
On forward earnings alone, Capital Southwest Corporation (CSWC) trades at 10.
1x forward P/E versus 40. 7x for Gladstone Investment Corporation — 30. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MRCC: 57. 5% to $8. 00.
08Which pays a better dividend — CDT or MRCC or CSWC or GAIN?
In this comparison, CSWC (10.
2% yield), GAIN (10. 0% yield), MRCC (0. 2% yield) pay a dividend. CDT does not pay a meaningful dividend and should not be held primarily for income.
09Is CDT or MRCC or CSWC or GAIN better for a retirement portfolio?
For long-horizon retirement investors, Gladstone Investment Corporation (GAIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53), 10. 0% yield, +319. 3% 10Y return). CDT Equity Inc. (CDT) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GAIN: +319. 3%, CDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CDT and MRCC and CSWC and GAIN?
These companies operate in different sectors (CDT (Healthcare) and MRCC (Financial Services) and CSWC (Financial Services) and GAIN (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
CSWC, GAIN pay a dividend while CDT, MRCC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.